Investment Thesis
Spyre Therapeutics is a pre-revenue biotech company facing critical funding runway of approximately 6 months, with annual operating cash burn of $169.3M against $85.7M in liquid assets. While the company maintains a debt-free balance sheet with $777.8M in total assets, the severe cash burn rate relative to remaining capital, combined with zero revenue generation, creates imminent execution risk requiring either significant capital raises, substantial burn reduction, or near-term regulatory/clinical success.
Strengths
- Zero debt burden with clean balance sheet (Debt/Equity: 0.00x)
- Substantial asset base of $777.8M provides strategic flexibility
- Excellent liquidity position with 13.25x current ratio
Risks
- Critical cash runway of approximately 6 months at current burn rate
- Extreme cash burn of $169.3M annually with zero revenue offsetting losses
- Complete dependence on capital markets access or clinical milestone achievement for survival
Key Metrics to Watch
- Quarterly operating cash burn rate and cash position trends
- Clinical trial progress and regulatory filing timeline for lead candidates
- Capital raise announcements and debt facility changes
Financial Metrics
Revenue
0.0
Net Income
-155.2M
EPS (Diluted)
$-1.24
Free Cash Flow
-169.3M
Total Assets
777.8M
Cash
85.7M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-21.7%
ROA
-20.0%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
13.25x
Quick Ratio
13.25x
Debt/Equity
0.00x
Debt/Assets
8.0%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-17T01:33:26.866091 |
Data as of: 2025-12-31 |
Powered by Claude AI